AM-Pharma is a Dutch clinical stage biopharmaceutical company developing a treatment for acute kidney injury (AKI) that could be lifesaving. The Company does not produce face masks or other medical equipment.
OUR INVESTORS
LATEST NEWS
- AM-Pharma Increases Funding to €163m for Phase-III Trial of recAP in SA-AKI 31 March 2020
- AM-Pharma vergroot met extra €47 miljoen de financiering voor klinische fase III-registratiestudie met Nederlands kandidaatmedicijn tegen acuut nierfalen tot €163 miljoen 31 March 2020
- AM-Pharma Expands its Senior Team in Preparation for a Pivotal Phase III Trial of recAP in Acute Kidney Injury 1 October 2019
